anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent controversies over the mismanagement of body donors in US medical schools have raised public concerns over the ethical treatment of bodies in "anatomical gift" programs. Despite widespread moral outrage at such cases, medical students may still make seemingly inconsequential mistakes or jokes that in fact constitute acts of disrespect. This may partially be attributed to the process of desensitization in working with human remains, and indicates a further need to inculcate into medical students the ethical responsibilities of working with body donors. Donation agreement statements that lack specific information about the respectful treatment of bodies in the anatomy laboratory may serve as an additional point of concern for potential donors seeking reassurance about the future treatment of their bodies. This viewpoint draws from the anecdotal experiences of medical students to portray two scenarios of medical students' disrespectful conduct toward body donors, and constructs an account of moral respect for human remains based on respect for posthumous autonomy and respect in attitude. It then provides suggestions for US medical schools to incorporate this ethical framework into their anatomy curricula to instill respectful dispositions in its students and facilitate a more robust informed consent process for potential donors who entrust their bodies to medical students.
OBJECTIVE: While antiretroviral therapy (ART) is highly effective, detection of low levels of HIV-1 RNA in plasma is common in treated individuals. Given the uncertainties on the topic, we convened a panel of experts to consider different clinical scenarios, producing a Delphi consensus to help guide clinical practice.
METHODS: A panel of 17 experts in infectious diseases, virology and immunology rated 32 statements related to four distinct scenarios: (1) low-level viremia during stable (≥6 months) first-line ART (≥2 consecutive HIV-1 RNA measurements 50-500 copies/mL); (2) a viral blip during otherwise suppressive ART (a HIV-1 RNA measurement 50-1000 copies/mL with adjacent measurements <50 copies/mL); (3) low-level viral rebound during previously suppressive ART (≥2 consecutive HIV-1 RNA measurements 50-500 copies/mL); (4) residual viremia during suppressive ART (persistent HIV-1 RNA quantification below 50 copies/mL). A systematic review, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement, informed the 32 statements. The Delphi procedure was modified to include two voting rounds separated by a moderated group discussion. Grading of Recommendations, Assessment, Development, and Evaluations-based recommendations were developed.
RESULTS: Overall, 18/32 statements (56.2%) achieved a strong consensus, 3/32 (9.4%) achieved a moderate consensus and 11/32 (34.4%) did not achieve a consensus. Across the four scenarios, the panel unanimously emphasised the importance of implementing specific interventions prior to considering therapy changes, including assessing adherence, testing for genotypic drug resistance and scheduling more frequent follow-up visits. Strategies indicated in selected circumstances included therapeutic drug monitoring, quantifying total HIV-1 DNA and evaluating concomitant chronic infections.
CONCLUSIONS: While acknowledging the many uncertainties about source, significance and optimal management of low-level viremia during ART, the findings provide insights to help harmonise clinical practice. There is a need for well-designed randomised studies assessing different interventions to manage low-level viremia and future research regarding its definition.
BACKGROUND: T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) molecule is a key regulator of the immune response by exerting an inhibitory effect on various types of immune cells. Understanding the role of TIM-3 in hematopoietic stem cell transplantation (HSCT) may improve transplant outcomes. Our study evaluated the potential association between TIM-3 polymorphisms, namely rs1036199 (A > C) or rs10515746 (C > A), changes which are located in exon 3 and the promoter region of the TIM-3 gene, and post-HSCT outcomes.
METHODS: One-hundred and twenty allogeneic HSCT patients and their respective donors were enrolled and genotyped for TIM-3 single nucleotide polymorphisms (SNPs) using real-time PCR with TaqMan assays.
RESULTS: We found that the presence of the rare alleles and heterozygous genotypes of studied SNP in recipients tended to protect against or increase the risk for acute graft-versus-host disease (aGvHD). For the rs1036199 polymorphism, recipients with the AC heterozygous genotype (p = 0.0287) or carrying the rarer C allele (p = 0.0334) showed a lower frequency of aGvHD development along all I-IV grades. A similar association was detected for the rs10515746 polymorphism as recipients with the CA genotype (p = 0.0095) or the recessive A allele (p = 0.0117) less frequently developed aGvHD. Furthermore, the rarer A allele of rs10515746 SNP was also associated with a prolonged aGvHD-free survival (p = 0.0424). Cytomegalovirus (CMV) infection was more common in patients transplanted with TIM-3 rs10515746 mismatched donors (p = 0.0229) and this association was also found to be independent of HLA incompatibility and pre-transplant CMV-IgG status. Multivariate analyses confirmed the role of these recessive alleles and donor-recipient TIM-3 incompatibility as an independent factor in aGvHD and CMV development.
CONCLUSIONS: Polymorphism of TIM-3 molecule may affect the immune response in HSCT patients. The recessive alleles of rs1036199 and rs10515746 SNPs decreased the risk of developing aGvHD. TIM-3 donor-recipient genetic matching may also affect the risk of post-transplant CMV infection, indicating the potential value of genetic profiling in optimizing transplant strategies.
In a controlled clinical study in which Avastin was not administered within 28 days of major surgical procedures, the incidence of wound healing complications, including serious and fatal complications, was 15% in patients with mCRC who underwent surgery while receiving Avastin and 4% in patients who did not receive Avastin. In a controlled clinical study in patients with relapsed or recurrent GBM, the incidence of wound healing events was 5% in patients who received Avastin and 0.7% in patients who did not receive Avastin [see Adverse Reactions (6.1)].

In patients who experience wound healing complications during Avastin treatment, withhold Avastin until adequate wound healing. Withhold for at least 28 days prior to elective surgery. Do not administer for at least 28 days following major surgery and until adequate wound healing. The safety of resumption of AVASTIN after resolution of wound healing complications has not been established [see Dosage and Administration (2.9)].

Necrotizing fasciitis including fatal cases, has been reported in patients receiving Avastin, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation. Discontinue Avastin in patients who develop necrotizing fasciitis.
A hot-melt extruded composition having finely divided drug-containing particles dispersed within a carrier is provided. The carrier melts during extrusion but does not dissolve the drug. As a result a majority of the particles are noπaggregated during extrusion into crystalline or amorphous particles. Various excipients can be included in the carrier system to stabilize the particle size. A hydrophilic polymer can also be Included in the composition. A process for preparing the extrudate Is conducted at a temperature at or above the melting point of the matrix and below the point of solubilization of the drug-containing particles and below the rβcrystallization point of the amorphous fine-drug particles.
Methylphenidate (MPH) is commonly used to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of MPH in treating adult cocaine dependent individuals who are also diagnosed with ADHD.

Participants in this 14-week, double-blind, placebo-controlled study will be randomly assigned to receive either sustained-release MPH or placebo. All participants will receive individual cognitive behavioral therapy. The trial will last 14 weeks. It will include a 1-week placebo lead-in phase and a 2-week dose titration phase, followed by 11 weeks on a stable dose of MPH. During the titration phase, MPH will be given twice a day, starting at a dose of 10 mg/day. The dose will increase by 10 mg each day, until a final stable dose of 40 mg/day is reached. At this time, sustained-release MPH will be given as two 20 mg doses (one in the morning and one in the afternoon). Depending on a participant's tolerance of MPH, the dose will be increased to a maximum of 60 mg/day (40 mg in the morning and 20 mg in the afternoon). Participants who are unable to tolerate a dose of at least 40 mg/day of MPH will be discontinued from the study. Assessments of ADHD symptoms will be completed at weekly study visits. In addition, drug use assessments will also be completed and will include self-reports and urine toxicology tests.
PURPOSE:To provide the subject excellent promoter active at low dose, containing, as the active ingredient for a relevant external preparation, diisopropyl-1,3-dithiol-2-ylidenemalonate. CONSTITUTION:The objective dermal wound curing promoter can be obtained by formulating (A) pref. 0.05-10 (esp. 0.1-3)wt.% of diisopropyl-1,3-dithiol-2- ylidenemalonate (referred to as malotirate) in (B) a base. This promoter can be made into an ointment, cream, lotion, cataplasm, solution, etc., by formulation in an external base. An external preparation for the malotirate has effects entirely inexpectable from those for its oral administration; for example, on administering a malotirate cream, the reduction in the area of wounded sites can be promoted at any concentration.
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.
OBJECTIVE: This study investigates menopausal symptoms, household stressors, and ethnopolitical problems in relation to stress markers, including chronic stress measured by fingernail cortisol, perceived stress measured by the Perceived Stress Scale, and acute stress measured by blood pressure.
METHODS: Data from 151 women aged 40 to 55 years were collected from four regions in Nagaland, India, using opportunity sampling. A structured questionnaire was used to collect sociodemographic and lifestyle variables. Symptoms were grouped into emotional instability, vasosomatic symptoms, mood disturbances, and aches and pains using principal component analysis in a previous study, and stress markers included fingernail cortisol, perceived stress, and blood pressure. Community-level, household-level, and midlife symptoms were included to ascertain stressors from different sources.
RESULTS: Our results revealed a significant positive association between a composite measure of emotional instability and stress assessed by fingernail cortisol ( β = 0.46, P < 0.001). In addition, there was a positive association between mood disturbances and fingernail cortisol ( β = 0.24, P < 0.05). This relationship persisted after controlling for body mass index, socioeconomic status, and menopausal status. In addition, household problems were positively associated with fingernail cortisol ( β = 0.25, P = 0.01).
CONCLUSIONS: These findings highlight the potential health impacts of the psychosocial stress response associated with domestic stressors such as financial strain and concerns about children and health.
FIELD: biotechnology, veterinary virology. SUBSTANCE: method involves the use of the novel strain of equine infectious anemia virus N "3-K-VNIITIBP-VIEV" for antigen preparing. Strain is grown in horse embryo skin and/or muscle, or lung, and/or kidney cells up to accumulation of viruses at titer 10 5  ID 50/ml. Viruses are concentrated by ultrafiltration by 10-20-fold, lipid envelope is separated by treatment with ether in cold and the end product that is peptide (molecular mass is 24-26 kDa) carrying group-specific antigen determinants is obtained. After the concentration stage viral material can be subjected for purification by high-speed centrifugation and ultracentrifugation additionally. After separation of lipid envelope obtained antigen is purified by affinity chromatography additionally. In this case the end product is immunoelectrophoretically pure peptide. Obtained cultural antigen is used for kit making for identification of antigen of equine infectious anemia virus. Kits for identification of antibodies are designated for diagnosis of equine infectious anemia in RDP or IFA. Kit for identification of antigen is designated for titration of antigen of equine infectious anemia virus in the process of culturing. Kit for identification of antibodies in RDP has cultural antigen and specific precipitating serum. Kit for identification of antibodies in IFA has cultural antigen for immobilization on solid carrier, polystyrene plate and antispecies immunoglobulin class G (Ig G) conjugated with horse radish peroxidase. Kit for identification of antigen has cultural antigen for immobilization on solid carrier, polystyrene plate and Ig G to equine infectious anemia virus conjugated with horse radish peroxidase. Kits for IFA have gelatin, substrate for peroxidase reaction carrying out, detergent and buffer solutions also. Kits can contain positive and negative controls also. EFFECT: enhanced sensitivity, standard specification and specificity of cultural antigen and kits for identification of antibodies and antigen. 18 cl, 6 ex
This study will develop a dataset of annotated smartphone usage in the context of PrEP adherence and nonadherence. In order to understand smartphone context, the investigators will utilize a digital pill system (DPS) to measure real-time PrEP ingestion events. Eligibility will be confirmed during the Screening Visit (Visit 1). During the Enrollment Visit (Visit 2), participants will complete a baseline quantitative assessment (e.g., sociodemographics, sexual history, attitudes about technology), receive training on the operation of the DPS and Beiwe, and will ingest their first digital pill dose under observation by study staff. Participants will be instructed to take one PrEP pill once daily while using the DPS and Beiwe app for 60 days. Participants will return for a study visit at the end of month one (Visit 3) for a refill of digital pills. Following a 24-hour period which no PrEP ingestion is detected by the DPS, participants will receive a brief online substance use and sexual risk survey, which will inform specific contexts of nonadherence. At the Month 1 Visit (Visit 3) and Month 2 Visit (Visit 4), timeline followback discussions will be conducted to better understand the context of any PrEP nonadherence events detected by the DPS, and phenotypic data collected by the Beiwe app, during the prior 30 days. At the Month 2 (Visit 4), the investigators will administer a blood draw for dried blood spot (DBS) testing to measure participants' PrEP adherence and compare it against adherence detected by the DPS. To gain insight into user experiences operating the DPS and Beiwe app as part of the study, the investigators will conduct the semi-structured qualitative exit interviews with participants at Month 2 (Visit 4).
1525984 Thiazole derivatives ROUSSEL UCLAF 28 Oct 1975 [29 Oct 1974] 44445/75 Heading C2C The invention comprises compounds of the formula wherein R1 represents a hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms; and R represents a hydrogen atom, an alkyl radical containing from 1 to 4 carbon atoms, an alkanoyl radical containing from 2 to 5 carbon atoms, a benzoyl radical, a phenyl radical optionally substituted by one or more halogen atoms, or a radical of formula (in which R 1 and R 2 , which may be the same or different, each represents a hydrogen atom or an alkyl radical containing from 1 to 3 carbon atoms, n is 0 or 1 and Z represents a phenyl radical optionally substituted by one or more halogen atoms); and when R1 represents a hydrogen atom, the alkali metal, alkaline earth metal and aluminium salts thereof, with the proviso that, when R represents an alkanoyl radical containing from 2 to 5 carbon atoms or a benzoyl radical, R1 represents an alkyl radical containing from 1 to 4 carbon atoms. Compounds wherein R1 represents an alkyl radical containing from 1 to 4 carbon atoms and R represents an alkyl radical containing from 1 to 4 carbon atoms, an alkanoyl radical containing 2 to 5 carbon atoms, a benzyl radical or a phenyl radical optionally substituted by one or more halogen atoms may be prepared by reacting together compounds of the formulµ where Hal represents a halogen atom. Compounds wherein R1 represents a hydrogen atom and R represents an alkyl radical containing from 1 to 4 carbon atoms or a phenyl radical optionally substituted by one or more halogen atoms may be prepared by hydrolysing the corresponding compounds wherein R is an alkyl radical containing from 1 to 4 carbon atoms. Compounds wherein R1 is an alkyl radical containing from 1 to 4 carbon atoms and R is a hydrogen atom, or wherein R1 and R are both hydrogen atoms may also be obtained by hydrolysis. Compounds wherein R represents a radical of Formula VII may be obtained by reacting a compound wherein R is a hydrogen atom with a compound of the formula The salts may be obtained by reacting the acid with an appropriate base. The compounds exhibit hypolipaemic, vasodilatory and hypocholesterolemic activity.
INTRODUCTION: Leptin is a pleiotropic hormone that regulates food intake and energy homeostasis with enigmatic effects on bone development. It is unclear if leptin promotes or inhibits bone growth. The aim of this study was to characterize the micro-architecture and mechanical competence of femur bones of leptin-deficient mice.
MATERIALS AND METHODS: Right femur bones of 15-week old C57BL/6 (n = 9) and leptin-deficient (ob/ob, n = 9) mice were analyzed. Whole bones were scanned using micro-CT and morphometric parameters of the cortex and trabeculae were assessed. Elastic moduli were determined from microindentations in midshaft cross-sections. Mineral densities were determined using quantitative backscatter scanning electron microscopy. 3D models of the distal femur metaphysis, cleared from trabecular bone, were meshed and used for finite element simulations of axial loading to identify straining differences between ob/ob and C57BL/6 controls.
RESULTS: Compared with C57BL/6 controls, ob/ob mice had significantly shorter bones. ob/ob mice showed significantly increased cancellous bone volume and trabecular thickness. qBEI quantified a ∼7% lower mineral density in ob/ob mice in the distal femur metaphysis. Indentation demonstrated a significantly reduced Young's modulus of 12.14 [9.67, 16.56 IQR] GPa for ob/ob mice compared to 23.12 [20.70, 26.57 IQR] GPa in C57BL/6 mice. FEA revealed greater deformation of cortical bone in ob/ob as compared to C57BL/6 mice.
CONCLUSION: Leptin deficient ob/ob mice have a softer cortical bone in the distal femur metaphysis but an excessive amount of cancellous bone, possibly as a response to increased deformation of the bones during axial loading. Both FEA and direct X-ray and electron microscopy imaging suggest that the morphology and micro-architecture of ob/ob mice have inferior biomechanical properties suggestive of a reduced mechanical competence.
Simvastatin is part of the pharmacotherapeutic group of HMG-CoA reductase inhibitors (ATC-Code: C10A A01). Simvastatin is licensed within the EU for hypercholesterolemia and cardiovascular prevention but for this trial its use will be outside its licensed indication. Oral Simvastatin will be taken 40mg daily (one tablet in the evening) for 4 weeks and then at week 4 up titrated to 80mg daily (two tablets in the evening.
Liver is one of the targets of cadmium (Cd) bioaccumulation for hepatic damage and pathologies via oxidative inflammation and apoptosis. The current study explored whether the citrus flavonoid naringenin (NAR) could prevent hepatic accumulation of Cd and Cd hepatotoxicity in a rat model. Rats in group 1 received normal saline; group 2 received NAR (50 mg/kg body weight); group 3 received CdCl2 (5 mg/kg body weight); group 4 received NAR + CdCl2, for four consecutive weeks. Assays related to markers of oxidative stress, inflammation, and apoptosis were carried out using liver homogenate. Blood and liver sample analyses revealed significant elevation of blood and hepatic Cd levels coupled with prominent increases in alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activities, whereas the albumin and total protein levels were decreased considerably. Hepatic superoxide dismutase (SOD), catalase (CAT), glutathione peroxide (GPx) activities diminished significantly compared to control followed by marked increases in malondialdehyde (MDA) levels, and dysregulation in caspase and cytokine (TNF-α, IL-6, IL-4, IL-10) levels. However, it was found that in the rats administered NAR + Cd, the levels of Cd, hepatic enzymes, MDA, TNF-α, IL-6, and caspases-3/-9 were prominently reduced compared to the Cd group. The hepatic SOD, CAT, GPx, IL-4, IL-10, albumin, and total protein were markedly elevated along with alleviated hepatic histopathological abrasions. Taken together therefore, NAR is a potential flavonoid for blocking hepatic Cd bioaccumulation and consequent inhibition of Cd-induced oxidative inflammation and apoptotic effects on the liver of rats.
An open-label, non-comparative, multicenter clinical study of LUPRON DEPOT 45 mg for 6-month administration enrolled 151 patients with prostate cancer. The study drug was administered as two intramuscular injections of LUPRON DEPOT 45 mg at 24 week intervals (139/151 received 2 injections), and patients were followed for a total of 48 weeks. 

Among 148 patients who had testosterone value at Week 4, serum testosterone was suppressed to castrate levels (< 50 ng/dL) from Week 4 through Week 48 in an estimated 93.4% (two-sided 95% CI: 89.2%, 97.6%) of patients. One patient failed to achieve testosterone suppression by Week 4, and eight patients had escapes from suppression (any testosterone value > 50 ng/dL after castrate levels were achieved). Mean testosterone levels increased to 608 ng/dL from a baseline of 435 ng/dL during the first week of treatment. By Week 4, the mean testosterone concentration had decreased to below castrate levels (16 ng/dL). 

Periodic monitoring of serum testosterone levels is recommended, especially if the anticipated clinical or biochemical response to treatment has not been achieved. Testosterone determinations are dependent on assay methodology and it is advisable to be aware of the type and precision of the assay methodology to make appropriate clinical and therapeutic decisions. 

Figure 11 below shows the mean testosterone concentration at various time points. 

Figure 11. LUPRON DEPOT 45 mg for 6-Month Administration Serum Testosterone Concentrations (Mean + SE)